Omalizumab (Xolair?) is a recombinant DNA-derived humanized IgG1k monoclonal antibody that selectively binds to human immunoglobulin E (IgE). Xolair inhibits the binding of IgE to the high-affinity IgE receptor (FceRI) on the surface of mast cells and basophils. Reduction in surface-bound IgE on FceRI-bearing cells limits the degree of release of mediators of the allergic response. Xolair is used to treat severe, persistent asthma. BioSim? Omalizumab ELISA kit has been developed for specific quantification of Omalizumab concentration in human serum or plasma with high sensitivity and reproducibility.
產(chǎn)品特點(diǎn)
? Easy, convenient, sensitive and time-saving method to measure the level of Omalizumab in human serum and plasma.
? Detection Range: 10 - 1000 ng/ml
? Sensitivity: 10 ng/ml
? Assay Precision: Intra-Assay: CV < 15%; Inter-Assay: CV < 15% (CV (%) = SD/mean X 100)
? Recovery rate: 85 – 115% with normal human serum samples with known concentrations
? Cross Reactivity: There is no cross reaction with native serum immunoglobulins and tested monoclonal antibodies such as infliximab (Remicade?), adalimumab (Humira?), etanercept (Enbrel?), bevacizumab (Avastin?), trastuzumab(Herceptin?)